The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Anadys Pharmaceuticals Inc.
20 10월 2011 - 2:12AM
Business Wire
Levi & Korsinsky is investigating the Board of Directors of
Anadys Pharmaceuticals Inc. (“Anadys” or the “Company”) (NASDAQ:
ANDS) for possible breaches of fiduciary duty and other violations
of state law in connection with the sale of the Company to Roche
Holding AG. Under the terms of the transaction, Anadys shareholders
will receive $3.70 in cash per share of Anadys stock they own. The
transaction is valued at approximately $230 million.
Click here to learn more about the investigation:
http://zlk.9nl.com/anadys-pharmaceuticals/, or call:
877-363-5972.
The investigation concerns whether the Anadys Board of Directors
breached their fiduciary duties to Anadys stockholders by failing
to adequately shop the Company before entering into this
transaction and whether Roche Holding AG is underpaying for Anadys
shares, thus unlawfully harming Anadys stockholders. Roche has said
that the proposed acquisition would boost its own portfolio of
hepatitis C drugs, which include Pegasys and Copegus. While the
deal is priced at $3.70 per share, at least one analyst has set a
price target for the stock of $4.00 per share.
If you own common stock in Anadys and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email
at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free:
(877) 363-5972, or visit http://www.zlk.com.
Levi & Korsinsky has expertise in prosecuting investor
securities litigation and extensive experience in actions involving
financial fraud and represents investors throughout the nation,
concentrating its practice in securities and shareholder
litigation. The attorneys at Levi & Korsinsky have been
appointed by numerous courts throughout the country to serve as
lead counsel on behalf of shareholders in major litigations
involving mergers and acquisitions. For more information, please
feel free to contact any of the attorneys listed below. Attorney
advertising. Prior results do not guarantee similar outcomes.
Anadys (NASDAQ:ANDS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Anadys (NASDAQ:ANDS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Anadys Pharmaceuticals (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Levi & Korsinsky, LLP News Articles